Sign inCreate account

Report workspace tools

NCT03608631RECRUITINGanonymous

Phase I Study of Mesenchymal Stromal Cells-Derived Exosomes With KrasG12D siRNA for Metastatic Pancreas Cancer Patients Harboring KrasG12D Mutation

Sponsor

Source record

M.D. Anderson Cancer Center

Phase

Source record

PHASE1

Modality

AI-normalized

cell therapy

Target

AI-normalized

Mesenchymal Stromal Cells-derived Exosomes with KRAS G12D siRNA

Indication / condition

AI-normalized

KRAS NP_004976.2:p.G12D

Intervention

Source record

Mesenchymal Stromal Cells-derived Exosomes with KRAS G12D siRNA

Source & freshness

Source record

NCT ID

NCT03608631

Original source

ClinicalTrials.gov

Source last updated

May 20, 2026

Ingested at

Jun 11, 2026

Internal sync

Jun 11, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT03608631

Title

Phase I Study of Mesenchymal Stromal Cells-Derived Exosomes With KrasG12D siRNA for Metastatic Pancreas Cancer Patients Harboring KrasG12D Mutation

Sponsor

M.D. Anderson Cancer Center

Status

RECRUITING

Phase

PHASE1

Condition raw

KRAS NP_004976.2:p.G12D, Metastatic Pancreatic Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8

Condition normalized

KRAS NP_004976.2:p.G12D, Metastatic Pancreatic Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8

Modality raw

cell therapy

Modality normalized

cell therapy

Target raw

Mesenchymal Stromal Cells-derived Exosomes with KRAS G12D siRNA

Target normalized

Mesenchymal Stromal Cells-derived Exosomes with KRAS G12D siRNA

Interventions

Mesenchymal Stromal Cells-derived Exosomes with KRAS G12D siRNA

Public preview

Source record

This phase I trial studies the best dose and side effects of mesenchymal stromal cells-derived exosomes with KrasG12D siRNA (iExosomes) in treating participants with pancreatic cancer with KrasG12D mutation that has spread to other places in the body. iExosomes may work better at treating pancreatic cancer.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

Phase I Study of Mesenchymal Stromal Cells-Derived Exosomes With KrasG12D siRNA for Metastatic Pancreas Cancer Patients Harboring KrasG12D Mutation

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT03608631

Status

RECRUITING

Phase

PHASE1

Sponsor

M.D. Anderson Cancer Center

Executive brief

Investment-Ready Snapshot

This phase I trial studies the best dose and side effects of mesenchymal stromal cells-derived exosomes with KrasG12D siRNA (iExosomes) in treating participants with pancreatic cancer with KrasG12D mutation that has spread to other places in the body. iExosomes may work better at treating pancreatic cancer.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedMay 20, 2026
Internal syncJun 11, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT03608631

Indication

KRAS NP_004976.2:p.G12D

Modality

cell therapy

Target

Mesenchymal Stromal Cells-derived Exosomes with KRAS G12D siRNA

Intervention

Mesenchymal Stromal Cells-derived Exosomes with KRAS G12D siRNA

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.